Company profile MRSN

Mersana Therapeutics Inc
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attack...ing a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments. Show More
Quarter analysis & expected interest

There is not enough data for Mersana Therapeutics near me to provide analysis

Correlation between past revenue and Mersana Therapeutics near me search interest

There is not enough data for Mersana Therapeutics near me to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Mersana Therapeutics near me to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Mersana Therapeutics login to provide analysis

Correlation between past revenue and Mersana Therapeutics login search interest

There is not enough data for Mersana Therapeutics login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Mersana Therapeutics login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 01:49:47.

After 38 days of this quarter the interest is at 20.0. Based on that we can calculate that during remaining 53 days it will total up to 48.0.
Mersana Therapeutics stock expected interest is significantly lower compared to previous quarter (-78.1%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2019106
31
-70.8% QoQ
120
287.1% QoQ
21
-82.5% QoQ
2020 42
-60.4% YoY 100.0% QoQ
174
461.3% YoY 314.3% QoQ
150
25.0% YoY -13.8% QoQ
68
223.8% YoY -54.7% QoQ
2021 140
233.3% YoY 105.9% QoQ
149
-14.4% YoY 6.4% QoQ
217
44.7% YoY 45.6% QoQ
201
195.6% YoY -7.4% QoQ
2022 251
79.3% YoY 24.9% QoQ
137
-8.1% YoY -45.4% QoQ
72
-66.8% YoY -47.4% QoQ
135
-32.8% YoY 87.5% QoQ
2023 54
-78.5% YoY -60.0% QoQ
194
41.6% YoY 259.3% QoQ
430
497.2% YoY 121.6% QoQ
219
62.2% YoY -49.1% QoQ
2024 20
-63.0% YoY -90.9% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Mersana Therapeutics stock search interestLast update: February 08 2024 01:49:46.
Correlation coefficient between keyword and revenue is -0.04
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 01:49:47.

The average 5 years interest of Mersana Therapeutics stock was 11.23 per week.
The last year interest of Mersana Therapeutics stock compared to the last 5 years has changed by 53.43%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 180.16%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for XMT-1660 Mersana Therapeutics to provide analysis

Correlation between past revenue and XMT-1660 Mersana Therapeutics search interest

There is not enough data for XMT-1660 Mersana Therapeutics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for XMT-1660 Mersana Therapeutics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for XMT-2056 Mersana Therapeutics to provide analysis

Correlation between past revenue and XMT-2056 Mersana Therapeutics search interest

There is not enough data for XMT-2056 Mersana Therapeutics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for XMT-2056 Mersana Therapeutics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Mersana Therapeutics cancer treatment to provide analysis

Correlation between past revenue and Mersana Therapeutics cancer treatment search interest

There is not enough data for Mersana Therapeutics cancer treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Mersana Therapeutics cancer treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Mersana Therapeutics clinical trials to provide analysis

Correlation between past revenue and Mersana Therapeutics clinical trials search interest

There is not enough data for Mersana Therapeutics clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Mersana Therapeutics clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Mersana Therapeutics collaboration to provide analysis

Correlation between past revenue and Mersana Therapeutics collaboration search interest

There is not enough data for Mersana Therapeutics collaboration to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Mersana Therapeutics collaboration to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Mersana Therapeutics CEO to provide analysis

Correlation between past revenue and Mersana Therapeutics CEO search interest

There is not enough data for Mersana Therapeutics CEO to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Mersana Therapeutics CEO to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for MRSN
Earnings date: 2024-02-28 After close
Company name: Mersana Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-01-06T14:02:10Z

GlobeNewswire
Day One Completes Acquisition of Mersana Therapeutics

2025-12-23T18:55:00-05:00

PR Newswire
Halper Sadeh LLC Encourages UDMY, ALEX, UBFO, MRSN Shareholders to Contact the Firm to Discuss Their Rights

2025-12-17T12:06:00-05:00

PR Newswire
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights

2025-12-16T11:31:00-05:00

PR Newswire
Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

2025-12-12T16:42:00-05:00

PR Newswire
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN

2025-12-08T14:40:00-05:00

PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI

2025-11-28T12:41:00-05:00

PR Newswire
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights

2025-11-27T23:11:00-05:00

PR Newswire
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN

2025-11-17T12:00:00-05:00

PR Newswire
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights

2025-11-14T15:19:00-05:00

PR Newswire
Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights

2025-11-14T14:15:05Z

Analyst Upgrades
Guggenheim Downgrades Mersana Therapeutics to Neutral

2025-11-14T12:00:00Z

GlobeNewswire
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

2025-11-13T18:00:08Z

Analyst Upgrades
Truist Securities Downgrades Mersana Therapeutics to Hold, Lowers Price Target to $30.75

2025-11-13T17:45:47Z

Analyst Upgrades
BTIG Downgrades Mersana Therapeutics to Neutral

2025-11-13T11:35:00-05:00

PR Newswire
Shareholder Alert: The Ademi Firm investigates whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders